Influenza Vaccine Effectiveness Against 2009 Pandemic Influenza A(H1N1) Virus Differed by Vaccine Type During 2013–2014 in the United States
Open Access
- 6 January 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 213 (10), 1546-1556
- https://doi.org/10.1093/infdis/jiv577
Abstract
Background. The predominant strain during the 2013–2014 influenza season was 2009 pandemic influenza A(H1N1) virus (A[H1N1]pdm09). This vaccine-component has remained unchanged from 2009. Methods. The US Flu Vaccine Effectiveness Network enrolled subjects aged ≥6 months with medically attended acute respiratory illness (MAARI), including cough, with illness onset ≤7 days before enrollment. Influenza was confirmed by reverse-transcription polymerase chain reaction (RT-PCR). We determined the effectiveness of trivalent or quadrivalent inactivated influenza vaccine (IIV) among subjects ages ≥6 months and the effectiveness of quadrivalent live attenuated influenza vaccine (LAIV4) among children aged 2–17 years, using a test-negative design. The effect of prior receipt of any A(H1N1)pdm09-containing vaccine since 2009 on the effectiveness of current-season vaccine was assessed. Results. We enrolled 5999 subjects; 5637 (94%) were analyzed; 18% had RT-PCR–confirmed A(H1N1)pdm09-related MAARI. Overall, the effectiveness of vaccine against A(H1N1)pdm09-related MAARI was 54% (95% confidence interval [CI], 46%–61%). Among fully vaccinated children aged 2–17 years, the effectiveness of LAIV4 was 17% (95% CI, −39% to 51%) and the effectiveness of IIV was 60% (95% CI, 36%–74%). Subjects aged ≥9 years showed significant residual protection of any prior A(H1N1)pdm09-containing vaccine dose(s) received since 2009, as did children Conclusions. During 2013–2014, IIV was significantly effective against A(H1N1)pdm09. Lack of LAIV4 effectiveness in children highlights the importance of continued annual monitoring of effectiveness of influenza vaccines in the United States.Keywords
Funding Information
- National Institutes of Health (UL1 RR024153, UL1TR000005)
This publication has 44 references indexed in Scilit:
- The case test-negative design for studies of the effectiveness of influenza vaccineVaccine, 2013
- Effectiveness of 1 Dose of Influenza A (H1N1) 2009 Monovalent Vaccines in Preventing Reverse-Transcription Polymerase Chain Reaction-Confirmed H1N1 Infection Among School-Aged Children in MaineThe Journal of Infectious Diseases, 2012
- Immunogenicity and Safety of a Quadrivalent Live Attenuated Influenza Vaccine in ChildrenThe Pediatric Infectious Disease Journal, 2012
- A Sentinel Platform to Evaluate Influenza Vaccine Effectiveness and New Variant Circulation, Canada 2010–2011 SeasonClinical Infectious Diseases, 2012
- I-MOVE Multi-Centre Case Control Study 2010-11: Overall and Stratified Estimates of Influenza Vaccine Effectiveness in EuropePLOS ONE, 2011
- A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adultsVaccine, 2011
- Effectiveness of Non-Adjuvanted Pandemic Influenza A Vaccines for Preventing Pandemic Influenza Acute Respiratory Illness Visits in 4 U.S. CommunitiesPLOS ONE, 2011
- Age-Specific Effectiveness of an Oil-in-Water Adjuvanted Pandemic (H1N1) 2009 Vaccine Against Confirmed Infection in High Risk Groups in EnglandThe Journal of Infectious Diseases, 2011
- Correlation of Cellular Immune Responses with Protection against Culture-Confirmed Influenza Virus in Young ChildrenClinical and Vaccine Immunology, 2008
- Comparison of the Efficacy and Safety of Live Attenuated Cold-Adapted Influenza Vaccine, Trivalent, With Trivalent Inactivated Influenza Virus Vaccine in Children and Adolescents With AsthmaThe Pediatric Infectious Disease Journal, 2006